The role of radiological imaging for masses in the prevascular mediastinum in clinical practice.
Mediastinal tumors
mediastinal lymphoma
mediastinal teratoma
thymoma
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
ppublish
Résumé
Tumors in the prevascular compartment of the mediastinum are rare and imaging plays a major role in their detection, (differential) diagnosis, staging, and follow-up. The prevascular compartment is bordered anteriorly by the posterior aspect of the sternum, posteriorly by the ventral aspect of the pericardium, cranially by the thoracic outlet, and caudally by the diaphragm. In many cases, the diagnosis of a lesion in the prevascular compartment is an incidental finding either on chest radiograph (CR) or on computed tomography (CT) scans. The differential diagnosis of masses in the pre-vascular mediastinum include primarily tumors arising from the thymus or the thyroid gland, lymphomas and germ cell tumors. The differential diagnosis of mediastinal masses is primarily based on the location of the mass, its tissue composition (i.e., fat content, calcifications) and the age of the patient. The imaging method of choice is CT, as it combines a high spatial and temporal resolution with the ability to determine tissue composition and detect fluid components, as well as areas of fat and calcifications. MRI is used as a more specific problem-solving tool to discriminate solid lesions from cystic lesions or to provide evidence of minimal fat content in teratoma and thymic rebound. The role of PET/CT in the evaluation of tumors other than lymphomas in the prevascular compartment is still under discussion.
Identifiants
pubmed: 33447449
doi: 10.21037/jtd-20-964
pii: jtd-12-12-7591
pmc: PMC7797866
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
7591-7597Informations de copyright
2020 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at: http://dx.doi.org/10.21037/jtd-20-964). The series “Thymoma” was commissioned by the editorial office without any funding or sponsorship. HP reports grants and personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from MSD, personal fees from BMS, personal fees from AstraZeneca, personal fees from Siemens, outside the submitted work. The other authors have no conflicts of interest to declare.
Références
Radiographics. 2017 Mar-Apr;37(2):413-436
pubmed: 28129068
Eur J Radiol. 2009 Feb;69(2):280-8
pubmed: 18023547
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S110-8
pubmed: 25396307
Radiographics. 2010 Mar;30(2):413-28
pubmed: 20228326
J Thorac Oncol. 2011 Jul;6(7):1274-81
pubmed: 21623235
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S65-72
pubmed: 25396314
J Thorac Imaging. 2015 Jul;30(4):247-67
pubmed: 26086589
Cancer Imaging. 2007 Oct 01;7 Spec No A:S56-62
pubmed: 17921091
Clin Cancer Res. 2014 Jun 1;20(11):2984-93
pubmed: 24696320
Radiology. 2013 Jul;268(1):245-53
pubmed: 23440318
Eur J Radiol. 2015 Mar;84(3):524-533
pubmed: 25575742
AJR Am J Roentgenol. 2014 Aug;203(2):W128-38
pubmed: 25055288